United States-based Bon Secours Mercy Health, a Catholic health care system, has collaborated with United States-based Lirio LLC, a behavioural engagement solution, it was reported yesterday.
The strategic partnership was announced at the 38th annual JP Morgan Healthcare Conference and was initiated by a direct investment from Bon Secours Mercy Health in Lirio's behaviour change AI platform. John Starcher, president and CEO of Bon Secours Mercy Health will join Lirio's board of directors.
Both firms will co-develop new behaviour change programs that influence health decision-making for those at risk for chronic diseases, such as diabetes and hypertension. These programs will gradually be marketed and sold to other health systems globally under commercial terms agreed to between both parties. Bon Secours Mercy Health will license and install present Lirio behaviour change programs, such as women's health programs and programs that encourage the use of digital engagement tools like patient portals.
Gan & Lee presents trial results for novel diabetes therapies at ADA's 85th Scientific Sessions
TME Pharma and SERI partner to advance NOX-E36 in ophthalmology through option framework agreement
Innovent reports first participant dosed in new Phase 3 trial of mazdutide in China
Vivoryon Therapeutics presents positive meta-analysis data for varoglutamstat
Camurus and Lilly agree licensing deal for FluidCrystal incretins
Genprex signs new research agreement with University of Pittsburgh to advance diabetes gene therapy
FDA accepts Novo Nordisk's filing application for oral semaglutide 25 mg